Howland Capital Management LLC Purchases 341 Shares of Zoetis Inc. (NYSE:ZTS)

Howland Capital Management LLC lifted its position in Zoetis Inc. (NYSE:ZTS) by 15.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,594 shares of the company’s stock after buying an additional 341 shares during the period. Howland Capital Management LLC’s holdings in Zoetis were worth $423,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. Darwin Wealth Management LLC bought a new stake in shares of Zoetis in the third quarter worth about $31,000. First Personal Financial Services acquired a new position in shares of Zoetis in the 3rd quarter valued at approximately $33,000. Capital Performance Advisors LLP bought a new stake in Zoetis during the 3rd quarter worth approximately $33,000. Dunhill Financial LLC raised its holdings in Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after buying an additional 75 shares during the period. Finally, Fortitude Family Office LLC lifted its stake in Zoetis by 1,387.5% in the third quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after buying an additional 222 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ZTS. UBS Group initiated coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective for the company. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Stifel Nicolaus cut their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Morgan Stanley decreased their price objective on Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Finally, Leerink Partners began coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $215.00.

Zoetis Trading Down 1.6 %

Shares of Zoetis stock opened at $171.37 on Monday. The stock has a market cap of $77.32 billion, a P/E ratio of 32.21, a P/E/G ratio of 2.77 and a beta of 0.90. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.53. The business’s 50 day moving average is $169.26 and its 200-day moving average is $179.22.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.17%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is currently 37.59%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.